| London Stock Exchange: AGL
ANGLE Plc operates as a holding company, the company through its subsidiaries, Parsortix, Inc., Novocellus Ltd. and Geomerics Ltd. provides products in cancer diagnostics and foetal health and computer graphics technology platform services. The company operates through four segments: Controlled Investments in Medical Diagnostics, Non-Controlled Investments, Ventures and Management Services. The Controlled Investments in Medical Diagnostics comprises Parsortix, Novocellus and NeuroTargets. The Non-Controlled Investments segment comprises geomerics and the earn-out in relation to the sale of acolyte biomedica. The Ventures segment activities to establish, develop and create value in technology companies. The Management Services segment provision of management services to clients including research organisations, corporate and governmental organisations on a fee-for-service basis. ANGLE was founded by Andrew Newland in April 1994 and is headquartered in Guildford, the United Kingdom.